Trial Profile
A Multicenter Phase II Clinical Trial Assessing the Efficacy of the Combination of Lapatinib and Capecitabine in Patients With Non Pretreated Brain Metastasis From HER2 Positive Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms LANDSCAPE
- 29 Sep 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
- 29 Sep 2012 Primary endpoint 'Objective-clinical-response-rate' has been met.
- 06 Sep 2009 New trial record